Developer docs
API playgroundTry for free, no card

Search company profiles

Yuria-pharm

Full company profile

uuid0002sh9

Namestring
Yuria-pharm
Legal namestring
ЮРіЯ-ФАРМ
Websiteurl
uf.ua
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Yuria-pharm (ЮРіЯ-ФАРМ) is a privately held Ukrainian pharmaceutical group founded in 1998 that manufactures and distributes a broad portfolio of drugs and medical devices. The company operates 41 production lines across 25,000 m2 in Ukraine and 7 lines across 3,000 m2 at Diaco in Italy, with combined annual capacity exceeding 290 million units (204 million medicines and 86 million medical devices). Its 600+ registered products span infusion solutions (Reosorbilakt, Tivortin, Karnivit, Latren, Sorbilakt), antibiotics and antiseptics (Leflocin, Dekasan, Gynodek), cardiovascular and neurology products (Xavron/edavarone, Biblok, Neurocitin), respiratory therapies (Ulaizer Home nebuliser, Budesonide/Formoterol Easyhaler), medical devices (Revul hemostatic bandages, U-PORT implanted ports, Artro-Patch hyaluronic acid joint treatments, Dialiatek PD peritoneal dialysis), and functional waters (Izota, ReO, Laqua, Empati). Since 2015, the YP Biotech subsidiary has been building full-cycle biotechnological R&D infrastructure, including mRNA vaccine development, and 20+ new drugs are registered each year.

The company monetises primarily through one-time sales of pharmaceutical products and medical devices to hospitals, pharmacies, and government buyers, supplemented by hardware sales of devices and distributor/transaction-fee flows through its wholly-owned Medical Center M.T.K. distribution arm and 33,000 m2 of warehouse capacity. It is the #3 hospital distributor in Ukraine with 7.8% hospital market share, 13.4% share in parenteral products, and 3.3% of the overall Ukrainian pharmaceutical market. Exports to 41+ countries account for 25% of revenue, with recent geographic expansion into Central Asia via the 2024 acquisition of Reka-Med. Customers include Ukrainian hospitals and clinics, the Armed Forces of Ukraine and National Guard of Ukraine (notably for hemostatic products), and international distribution partners; the firm reinvests 90% of profits and targets +20% growth annually.

Short descriptiontext

Yuria-pharm (ЮРіЯ-ФАРМ) is a privately held Ukrainian pharmaceutical group manufacturing infusion solutions, specialty drugs, and medical devices across 600+ registrations, serving hospitals, pharmacies, military buyers, and 41+ export markets via its own distribution network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersKyiv, Ukraine
HQ citystring
Kyiv
HQ countrystring
Ukraine
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, infusion solutions, medical devices, biopharmaceutical R&D, hospital drug distribution
Industry1 code
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Manufacturing
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Products
TypeOne Time License
Description

Sale of registered pharmaceutical drugs including infusion solutions, cardiovascular drugs, antibiotics, analgesics, and specialty medications through hospital and retail channels

uf.ua
2Medical Devices
TypeHardware Sales
Description

Sale of medical devices including inhalation systems (Ulaizer, Breather), hemostatic bandages (Revul), surgical supplies, and diagnostic equipment

uf.ua
3Hospital Distribution Services
TypeTransaction Fee
Description

Distribution of pharmaceutical products through own distribution network (Medical Center M.T.K.) serving healthcare facilities across Ukraine

uf.ua
4International Export
TypeOne Time License
Description

Export of pharmaceutical products to 41+ countries worldwide, including Central Asia, with 25% of company revenue coming from exports

uf.ua
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1YP Biotech
Description

Biotechnology R&D division developing full-cycle biotechnological products including mRNA vaccines and biopharmaceutical active pharmaceutical ingredients

uf.ua
+2 more records
Core offering1 text field

Yuria-pharm manufactures and distributes a comprehensive portfolio of over 600 registered pharmaceutical products, including infusion solutions, antibiotics, cardiovascular drugs, antiseptics, and respiratory medications, along with medical devices such as hemostatic bandages, nebulizers, and implanted port systems. The company operates its own hospital distribution network (Medical Center M.T.K.) and produces 290+ million units annually across 41 production lines in Ukraine and 7 in Italy, exporting to 41+ countries. Yuria-pharm also conducts biotech R&D through YP Biotech, including mRNA vaccine development and hyaluronic acid-based therapeutic products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Market leader position: #3 hospital distributor in Ukraine with 7.8% hospital market share
+4 more records
Product overview1 text field

ЮРіЯ-ФАРМ is a Ukrainian pharmaceutical group with one of the most comprehensive portfolios in the country, holding 600+ registration certificates and producing over 290 million units annually. The product portfolio is organized as a multi-category platform consisting of: (1) Infusion Solutions including Реосорбілакт®, Тівортін®, Карнівіт®, Тіворель®, Латрен®, Гекодез®, Сорбілакт®, Ксилат® for detoxification, cardiovascular, metabolic, and critical care applications; (2) Antibiotics and Antimicrobials including Лефлоцин®, Цефтриаксон, Декасан®, Гінодек®; (3) Respiratory Products including Юлайзер™ Home nebulizer system, Будесонід Ізіхейлер®, Формотерол Ізіхейлер®, Небуфлюзон®; (4) Cardiovascular and Neurology including Ксаврон (edaravone for stroke), Біблок®, Нейроцитин®; (5) Medical Devices including Ревул® hemostatic products, Емаплаг, Ю-ПОРТ implanted port systems, Діавітек peritoneal dialysis; (6) Functional Waters including Ізотa (heartburn relief), ReO (rehydration), Laqua® (medication water), Емпаті (mental health); (7) Antiseptics including Декасан®, Горостен®, Юсепт; (8) Medical Supplies including Ю-ФІКС plasters, surgical gloves, infusion sets. Manufacturing spans Ukraine (41 production lines, 25,000 m²) and Italy (Diaco - 7 lines, 3,000 m²).

Product and service1 record
1Reosorbilakt (Реосорбілакт®)
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Reka-Med has been welcomed into the Yuria-pharm group of companies to continue scaling operations in Central Asian countries. Reka-Med serves as a manufacturing site that will ensure supply of Yuria-pharm products in Central Asian markets and Ukraine. The company will implement Yuria-pharm quality systems and standards, positioning it as a quality benchmark for parenteral medicinal products.

2BioGENext Platform Participants
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

BioGENext is the first platform in Ukraine for interaction between scientists in biomedical sciences. Launched by Yuria-pharm R&D team, it creates a living space for exchange of experience, knowledge, and innovative ideas in biomedicine and biopharmaceutical development. The platform aims to foster quality innovative development through quality partnerships.

uf.ua
3State Institution Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research and development partnership for blood pathology and transfusion medicine; joint mailing list partner for healthcare professional communications

uf.ua
4PE Infuzia
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for healthcare professional communications and mailing list services

uf.ua
5Diaco (Italy)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Italian manufacturing partner with 7 production lines, 3,000 m2 facility, producing 33 million units annually. Part of Yuria-pharm's international manufacturing network complementing Ukrainian production capabilities.

uf.ua
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Farmak is the largest pharmaceutical manufacturer in Ukraine, producing a broad portfolio of generic and branded drugs. Directly comparable as a domestic Ukrainian pharma manufacturer competing for the same hospital and retail channels across the same therapeutic areas.

TypeDirect peer
Description

Darnitsa is a top-tier Ukrainian pharmaceutical manufacturer with a broad portfolio of finished dosage forms. Comparable in scale, therapeutic breadth, and primary market overlap with Yuria-pharm in Ukrainian hospital and retail distribution.

TypeBroad incumbent
Description

KRKA is a leading Slovenian generic pharmaceutical manufacturer with broad therapeutic coverage and strong presence across Central/Eastern Europe and CIS markets. Comparable as a regional pharmaceutical manufacturer with similar hospital-channel focus and geographic expansion profile.

TypeDirect peer
Description

Arterium is a Ukrainian pharmaceutical corporation combining manufacturing and distribution, producing branded and generic drugs. Comparable vertically integrated model and similar product categories targeting Ukrainian and CIS hospital segments.

TypeBroad incumbent
Description

Stada is a major European specialty and generics pharmaceutical company with operations across multiple European markets. Comparable broad therapeutic portfolio, focus on hospital injectables and infusion solutions, and similar international distribution footprint.

TypeBroad incumbent
Description

Polpharma is one of the largest pharmaceutical manufacturers in Central and Eastern Europe, producing APIs and finished dosage forms. Comparable regional manufacturing scale and presence across CEE/CIS markets with similar hospital-channel focus.

TypeEmerging player
Description

Alvotech is a biopharmaceutical company specializing in biosimilars and biologic manufacturing. Comparable as an emerging biotech-focused manufacturer investing in biopharmaceutical production capabilities, though focused on biosimilars rather than Yuria-pharm's broader small-molecule portfolio.

TypeRegional player
Description

Sopharma is a Bulgarian pharmaceutical manufacturer with strong presence in Bulgaria, CIS, and other Eastern European markets. Comparable as a regional pharma manufacturer with similar generic/specialty portfolio and export-driven growth model.

TypeBroad incumbent
Description

Teva is the world's largest generic pharmaceutical manufacturer with a broad hospital injectables portfolio. Comparable in the infusion solutions and injectable generics therapeutic areas, though at vastly larger scale, representing a competitive incumbent in export markets.

TypeBroad incumbent
Description

Gedeon Richter is a Hungarian-headquartered pharmaceutical company with branded generic and specialty pharma operations across CEE/CIS regions. Comparable therapeutic breadth, regional footprint, and hospital/retail dual-channel model in Eastern European markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yuria-pharm

Pharmaceutical Manufacturinguf.ua

Yuria-pharm (ЮРіЯ-ФАРМ) is a privately held Ukrainian pharmaceutical group manufacturing infusion solutions, specialty drugs, and medical devices across 600+ registrations, serving hospitals, pharmacies, military buyers, and 41+ export markets via its own distribution network.

What Yuria-pharm does

Yuria-pharm (ЮРіЯ-ФАРМ) is a privately held Ukrainian pharmaceutical group founded in 1998 that manufactures and distributes a broad portfolio of drugs and medical devices. The company operates 41 production lines across 25,000 m2 in Ukraine and 7 lines across 3,000 m2 at Diaco in Italy, with combined annual capacity exceeding 290 million units (204 million medicines and 86 million medical devices). Its 600+ registered products span infusion solutions (Reosorbilakt, Tivortin, Karnivit, Latren, Sorbilakt), antibiotics and antiseptics (Leflocin, Dekasan, Gynodek), cardiovascular and neurology products (Xavron/edavarone, Biblok, Neurocitin), respiratory therapies (Ulaizer Home nebuliser, Budesonide/Formoterol Easyhaler), medical devices (Revul hemostatic bandages, U-PORT implanted ports, Artro-Patch hyaluronic acid joint treatments, Dialiatek PD peritoneal dialysis), and functional waters (Izota, ReO, Laqua, Empati). Since 2015, the YP Biotech subsidiary has been building full-cycle biotechnological R&D infrastructure, including mRNA vaccine development, and 20+ new drugs are registered each year.

The company monetises primarily through one-time sales of pharmaceutical products and medical devices to hospitals, pharmacies, and government buyers, supplemented by hardware sales of devices and distributor/transaction-fee flows through its wholly-owned Medical Center M.T.K. distribution arm and 33,000 m2 of warehouse capacity. It is the #3 hospital distributor in Ukraine with 7.8% hospital market share, 13.4% share in parenteral products, and 3.3% of the overall Ukrainian pharmaceutical market. Exports to 41+ countries account for 25% of revenue, with recent geographic expansion into Central Asia via the 2024 acquisition of Reka-Med. Customers include Ukrainian hospitals and clinics, the Armed Forces of Ukraine and National Guard of Ukraine (notably for hemostatic products), and international distribution partners; the firm reinvests 90% of profits and targets +20% growth annually.

Yuria-pharm firmographics

Firmographics
Name
Yuria-pharm
Legal name
ЮРіЯ-ФАРМ
Website
https://uf.ua
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
251–500 employees
Short description
Yuria-pharm (ЮРіЯ-ФАРМ) is a privately held Ukrainian pharmaceutical group manufacturing infusion solutions, specialty drugs, and medical devices across 600+ registrations, serving hospitals, pharmacies, military buyers, and 41+ export markets via its own distribution network.
Ownership category
akta.pro rank

Yuria-pharm industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAA
Primary Care & General Medicine Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Pharmaceutical manufacturing
  • Infusion solutions
  • Medical devices
  • Biopharmaceutical R&D
  • Hospital drug distribution

Where Yuria-pharm is headquartered

Location

Headquarters

HQ city
Kyiv
HQ country
Ukraine
HQ region
Europe

Offices5 records

Markets served

Yuria-pharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Products: Sale of registered pharmaceutical drugs including infusion solutions, cardiovascular drugs, antibiotics, analgesics, and specialty medications through hospital and retail channels
  2. Medical Devices: Sale of medical devices including inhalation systems (Ulaizer, Breather), hemostatic bandages (Revul), surgical supplies, and diagnostic equipment
  3. Hospital Distribution Services: Distribution of pharmaceutical products through own distribution network (Medical Center M.T.K.) serving healthcare facilities across Ukraine
  4. International Export: Export of pharmaceutical products to 41+ countries worldwide, including Central Asia, with 25% of company revenue coming from exports

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Yuria-pharm product offering

Product offering

Core offering

Yuria-pharm manufactures and distributes a comprehensive portfolio of over 600 registered pharmaceutical products, including infusion solutions, antibiotics, cardiovascular drugs, antiseptics, and respiratory medications, along with medical devices such as hemostatic bandages, nebulizers, and implanted port systems. The company operates its own hospital distribution network (Medical Center M.T.K.) and produces 290+ million units annually across 41 production lines in Ukraine and 7 in Italy, exporting to 41+ countries. Yuria-pharm also conducts biotech R&D through YP Biotech, including mRNA vaccine development and hyaluronic acid-based therapeutic products.

Product overview

ЮРіЯ-ФАРМ is a Ukrainian pharmaceutical group with one of the most comprehensive portfolios in the country, holding 600+ registration certificates and producing over 290 million units annually. The product portfolio is organized as a multi-category platform consisting of: (1) Infusion Solutions including Реосорбілакт®, Тівортін®, Карнівіт®, Тіворель®, Латрен®, Гекодез®, Сорбілакт®, Ксилат® for detoxification, cardiovascular, metabolic, and critical care applications; (2) Antibiotics and Antimicrobials including Лефлоцин®, Цефтриаксон, Декасан®, Гінодек®; (3) Respiratory Products including Юлайзер™ Home nebulizer system, Будесонід Ізіхейлер®, Формотерол Ізіхейлер®, Небуфлюзон®; (4) Cardiovascular and Neurology including Ксаврон (edaravone for stroke), Біблок®, Нейроцитин®; (5) Medical Devices including Ревул® hemostatic products, Емаплаг, Ю-ПОРТ implanted port systems, Діавітек peritoneal dialysis; (6) Functional Waters including Ізотa (heartburn relief), ReO (rehydration), Laqua® (medication water), Емпаті (mental health); (7) Antiseptics including Декасан®, Горостен®, Юсепт; (8) Medical Supplies including Ю-ФІКС plasters, surgical gloves, infusion sets. Manufacturing spans Ukraine (41 production lines, 25,000 m²) and Italy (Diaco - 7 lines, 3,000 m²).

Differentiator

Problem solved

Functional benefit

Brands

  • YP Biotech: Biotechnology R&D division developing full-cycle biotechnological products including mRNA vaccines and biopharmaceutical active pharmaceutical ingredients
  • BioGENext
  • YP Biotech

Products and services

  • Reosorbilakt (Реосорбілакт®)

Quantifiable outcome

  • Market leader position: #3 hospital distributor in Ukraine with 7.8% hospital market share
  • +4 more outcomes

Companies that use Yuria-pharm

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Yuria-pharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Yuria-pharm partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

  • Reka-MedcoreStrategic or Co-development Partner · 1 January 2024Reka-Med has been welcomed into the Yuria-pharm group of companies to continue scaling operations in Central Asian countries. Reka-Med serves as a manufacturing site that will ensure supply of Yuria-pharm products in Central Asian markets and Ukraine. The company will implement Yuria-pharm quality systems and standards, positioning it as a quality benchmark for parenteral medicinal products.
  • BioGENext Platform ParticipantsflagshipStrategic or Co-development Partner · 1 January 2024BioGENext is the first platform in Ukraine for interaction between scientists in biomedical sciences. Launched by Yuria-pharm R&D team, it creates a living space for exchange of experience, knowledge, and innovative ideas in biomedicine and biopharmaceutical development. The platform aims to foster quality innovative development through quality partnerships.
  • State Institution Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of UkrainecoreStrategic or Co-development PartnerResearch and development partnership for blood pathology and transfusion medicine; joint mailing list partner for healthcare professional communications
  • PE InfuziaminorStrategic or Co-development PartnerPartner for healthcare professional communications and mailing list services
  • Diaco (Italy)coreOEM/ Whitelabel/ Licensing PartnerItalian manufacturing partner with 7 production lines, 3,000 m2 facility, producing 33 million units annually. Part of Yuria-pharm's international manufacturing network complementing Ukrainian production capabilities.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Yuria-pharm competitors and assessment

Company assessment

Direct peers

  • Farmak: Farmak is the largest pharmaceutical manufacturer in Ukraine, producing a broad portfolio of generic and branded drugs. Directly comparable as a domestic Ukrainian pharma manufacturer competing for the same hospital and retail channels across the same therapeutic areas.
  • Darnitsa: Darnitsa is a top-tier Ukrainian pharmaceutical manufacturer with a broad portfolio of finished dosage forms. Comparable in scale, therapeutic breadth, and primary market overlap with Yuria-pharm in Ukrainian hospital and retail distribution.
  • Arterium: Arterium is a Ukrainian pharmaceutical corporation combining manufacturing and distribution, producing branded and generic drugs. Comparable vertically integrated model and similar product categories targeting Ukrainian and CIS hospital segments.

Broad incumbents

  • KRKA: KRKA is a leading Slovenian generic pharmaceutical manufacturer with broad therapeutic coverage and strong presence across Central/Eastern Europe and CIS markets. Comparable as a regional pharmaceutical manufacturer with similar hospital-channel focus and geographic expansion profile.
  • Stada Arzneimittel: Stada is a major European specialty and generics pharmaceutical company with operations across multiple European markets. Comparable broad therapeutic portfolio, focus on hospital injectables and infusion solutions, and similar international distribution footprint.
  • Polpharma: Polpharma is one of the largest pharmaceutical manufacturers in Central and Eastern Europe, producing APIs and finished dosage forms. Comparable regional manufacturing scale and presence across CEE/CIS markets with similar hospital-channel focus.
  • Teva Pharmaceutical: Teva is the world's largest generic pharmaceutical manufacturer with a broad hospital injectables portfolio. Comparable in the infusion solutions and injectable generics therapeutic areas, though at vastly larger scale, representing a competitive incumbent in export markets.
  • Gedeon Richter: Gedeon Richter is a Hungarian-headquartered pharmaceutical company with branded generic and specialty pharma operations across CEE/CIS regions. Comparable therapeutic breadth, regional footprint, and hospital/retail dual-channel model in Eastern European markets.

Emerging players

  • Alvotech: Alvotech is a biopharmaceutical company specializing in biosimilars and biologic manufacturing. Comparable as an emerging biotech-focused manufacturer investing in biopharmaceutical production capabilities, though focused on biosimilars rather than Yuria-pharm's broader small-molecule portfolio.

Regional players

  • Sopharma: Sopharma is a Bulgarian pharmaceutical manufacturer with strong presence in Bulgaria, CIS, and other Eastern European markets. Comparable as a regional pharma manufacturer with similar generic/specialty portfolio and export-driven growth model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Yuria-pharm social profiles

Digital presence

Yuria-pharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yuria-pharm leadership team

Management profile

Number of profiles

Profiles1 record

Yuria-pharm subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Yuria-pharm funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yuria-pharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yuria-pharm

What does Yuria-pharm do?

Yuria-pharm manufactures and distributes a comprehensive portfolio of over 600 registered pharmaceutical products, including infusion solutions, antibiotics, cardiovascular drugs, antiseptics, and respiratory medications, along with medical devices such as hemostatic bandages, nebulizers, and implanted port systems. The company operates its own hospital distribution network (Medical Center M.T.K.) and produces 290+ million units annually across 41 production lines in Ukraine and 7 in Italy, exporting to 41+ countries. Yuria-pharm also conducts biotech R&D through YP Biotech, including mRNA vaccine development and hyaluronic acid-based therapeutic products.

Is Yuria-pharm a public or private company?

Yuria-pharm is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Yuria-pharm founded?

Yuria-pharm was founded in 1998. It employs 251 to 500 people.

Where is Yuria-pharm based?

Yuria-pharm is headquartered in Kyiv, Ukraine, in the Europe region.

How does Yuria-pharm make money?

Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are medical Devices, hospital Distribution Services and international Export.

Who are Yuria-pharm's main competitors?

Direct peers on record are Farmak, Darnitsa and Arterium. Broad incumbents are KRKA, Stada Arzneimittel, Polpharma, Teva Pharmaceutical and Gedeon Richter. Alvotech is listed as an emerging player. Sopharma is listed as a regional player.

Does Yuria-pharm have an API?

No public API is recorded for Yuria-pharm.

What industry is Yuria-pharm in?

Yuria-pharm's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
UzdailyEBRD supports expansion of Ukrainian pharmaceutical company Yuria-Pharm in UzbekistanThe EBRD is providing €15 million to support Yuria-Pharm's cross-border expansion in Ukraine and Uzbekistan. The funds will expand production capacity, install solar panels, and improve energy efficiency in Uzbekistan, while supporting GMP certification and biopharmaceutical research in Ukraine. The company will also launch the bioGENext educational platform to address workforce shortages.Request BlockedEBRD supports leading Ukrainian pharma company Yuria-PharmEBRD lent €15 million to Ukrainian pharma company Yuria-Pharm to finance expansion in Ukraine and Uzbekistan. The loan will fund production upgrades, solar panels, and EU Good Manufacturing Practice certification, plus vocational training to address skills gaps.InventureEBRD lends €15 million to Ukraine's pharmaceutical producer Yuria-PharmThe EBRD lent €15 million to Ukraine's Yuria-Pharm to finance investments in Ukraine and Uzbekistan, including production expansion, solar panels, and EU Good Manufacturing Practice certification. The loan is backed by an EU guarantee under the 2024 Ukraine Investment Framework. Yuria-Pharm will also launch an educational platform to address labor shortages.Request BlockedEBRD supports leading Ukrainian pharma company Yuria-PharmThe EBRD is lending €15 million to Ukrainian pharma company Yuria-Pharm to finance cross-border growth in Ukraine and Uzbekistan. The funds will support production expansion, solar panels, and EU Good Manufacturing Practice certification, with a financial guarantee from the EU. Yuria-Pharm will also launch an educational platform to address labor shortages.UkrainerebuildnewsEBRD approves €15 million loan for Ukrainian Yuria Pharm Group's investments in Ukraine, Uzbekistan, LatviaThe EBRD approved a €15 million loan to co-finance Yuria Pharm Group's investment program in Uzbekistan, Ukraine, and Latvia for 2025-2027. The funding, focused on green projects and capex, is divided into €13 million committed and €2 million uncommitted tranches, both with a six-year tenor.Request BlockedWith help of EBRD finance, Ukraine’s YURiA-PHARM makes Uzbek acquisitionUkrainian pharma firm YURiA-PHARM acquired Uzbekistan's Reka-Med using €10 million of EBRD loan repurposed from an existing loan. The deal lets the company produce locally for Uzbekistan and free up 10% of Ukrainian production capacity for critical medicines. EBRD plans €3 billion in Ukraine investments for 2022-23.